Literature DB >> 12880959

The regulation of angiogenesis in neuroblastoma.

Alexandre Chlenski1, Shuqing Liu, Susan L Cohn.   

Abstract

Angiogenesis is required for the growth and metastasis of malignant tumors, and high vascular density has been correlated with aggressive tumor growth in many types of cancer. This process is regulated by the local balance of stimulatory and inhibitory molecules produced by tumor cells, stromal cells, and the organ-specific environment. In neuroblastoma, a pediatric malignancy that is characterized by a broad spectrum of clinical behavior, angiogenesis also appears to play an important role in determining tumor phenotype. The nature of the angiogenic balance in neuroblastoma is complex, and a spectrum of angiogenesis stimulators and inhibitors has been detected in neuroblastoma tumors. This review summarizes our current understanding of the regulation of angiogenesis in neuroblastoma.

Entities:  

Mesh:

Year:  2003        PMID: 12880959     DOI: 10.1016/s0304-3835(03)00082-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.

Authors:  Maria Peiris-Pagès; Steven J Harper; David O Bates; Pramila Ramani
Journal:  J Pathol       Date:  2010-10       Impact factor: 7.996

Review 3.  More than the genes, the tumor microenvironment in neuroblastoma.

Authors:  Lucia Borriello; Robert C Seeger; Shahab Asgharzadeh; Yves A DeClerck
Journal:  Cancer Lett       Date:  2015-11-17       Impact factor: 8.679

4.  Development and characterization of a human orthotopic neuroblastoma xenograft.

Authors:  Elizabeth Stewart; Anang Shelat; Cori Bradley; Xiang Chen; Sara Federico; Suresh Thiagarajan; Abbas Shirinifard; Armita Bahrami; Alberto Pappo; Chunxu Qu; David Finkelstein; Andras Sablauer; Michael A Dyer
Journal:  Dev Biol       Date:  2015-04-09       Impact factor: 3.582

5.  SPARC overexpression combined with radiation retards angiogenesis by suppressing VEGF-A via miR‑410 in human neuroblastoma cells.

Authors:  Jerusha Boyineni; Smita Tanpure; Manu Gnanamony; Reuben Antony; Karen S Fernández; Julian Lin; David Pinson; Christopher S Gondi
Journal:  Int J Oncol       Date:  2016-08-03       Impact factor: 5.650

Review 6.  Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions.

Authors:  Shweta Joshi
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

7.  Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development.

Authors:  Ariane Desselle; Tanguy Chaumette; Marie-Hélène Gaugler; Denis Cochonneau; Julien Fleurence; Nolwenn Dubois; Philippe Hulin; Jacques Aubry; Stéphane Birklé; François Paris
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

8.  PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.

Authors:  Karin Zins; Daniel Kovatchki; Trevor Lucas; Dietmar Abraham
Journal:  Int J Mol Sci       Date:  2016-09-23       Impact factor: 5.923

9.  Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.

Authors:  Anat Erdreich-Epstein; Donald L Durden; Alok R Singh; Shweta Joshi; Francisco M Vega; Pinzheng Guo; Jingying Xu; Susan Groshen; Wei Ye; Melissa Millard; Mihaela Campan; Guillermo Morales; Joseph R Garlich; Peter W Laird; Robert C Seeger; Hiroyuki Shimada
Journal:  Oncotarget       Date:  2016-11-18

Review 10.  The Tumor Microenvironment in Neuroblastoma: New Players, New Mechanisms of Interaction and New Perspectives.

Authors:  Laurence Blavier; Ren-Ming Yang; Yves A DeClerck
Journal:  Cancers (Basel)       Date:  2020-10-10       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.